The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Verve Therapeutics (NASDAQ:VERV) stock gains as the company wins the FDA fast track designation for VERVE-102, a cholesterol ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Verve Therapeutics (VERV) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for VERVE-102 for the ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Berberine is a powder made from different plants. It has many benefits, including improving blood sugar levels, reducing ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program ...

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...